N.neurology.org



Supplemental dataTable e-1. ICD and ATC codesStrokeIschemic strokeICD-8: 433; ICD-10: I63Unspecified strokeICD-8: 434; ICD-10: I64ICHICD-8: 431; ICD-10: I61SAHICD-8: 430; ICD-10: I60CT scanICD-10: UXCAMRI scanICD-10: UXMANSAIDsATC: M01A, except M01AX05Nonselective NSAIDsIbuprofenATC: M01AE01, M01AE51NaproxenATC: M01AE02KetoprofenATC: M01AE03, M01AE53DexibuprofenATC: M01AE14PiroxicamATC: M01AC01Tolfenamic acidATC: M01AG02COX-2 inhibitorsOlder COX2IsDiclofenacATC: M01AB05, M01AB55EtodolacATC: M01AB08NabumetonATC: M01AX01MeloxicamATC: M01AC06Newer COX2Is (coxibs)CelecoxibATC: M01AH01RofecoxibATC: M01AH02EtoricoxibATC: M01AH05ComedicationsACE or A2R InhibitorsATC: C09.A-DAcetylsalicylic acidATC: B01AC06, N02BA01BisphosphonatesATC: M05BA-BCalcium channel blockersATC: C08ClopidogrelATC: B01AC04SSRIsATC: N06ABStatinsATC: C10AA, C10B, B04ABSystemic glucocorticoidsATC: H02ABVitamin K antagonistsATC: B01AA03, B01AA04Other cardiovascular drugs Beta-blockersATC: C07DiureticsATC: C03NitratesATC: C01DAThrombolytic therapyATC: BOHA1Charlson Comorbidity IndexDiseasesWeightsMyocardial infarction1ICD-8: 410; ICD-10: I21; I22; I23Congestive heart failureICD-8: 427.09, 427.10, 427.11, 427.19, 428.99, 782.49; ICD-10: I50, I11.0, I13.0, I13.2Peripheral vascular diseaseICD-8: 440, 441, 442, 443, 444, 445; ICD-10: I70, I71, I72, I73, I74, I77Cerebrovascular diseaseICD-8: 430-438; ICD-10: I60-I69, G45, G46DementiaICD-8: 290.09-290.19, 293.09; ICD-10: F00-F03, F05.1, G30Chronic pulmonary diseaseICD-8: 490-493, 515-518, ICD-10: J40-J47, J60-J67, J68.4, J70.1, J70.3, J84.1, J92.0, J96.1, J98.2, J98.3Connective tissue diseaseICD-8: 712, 716, 734, 446, 135.99; ICD-10: M05, M06, M08, M09, M30, M31, M32, M33, M34, M35, M36, D86Ulcer diseaseICD-8: 530.91, 530.98, 531-534; ICD-10: K22.1, K25-K28Mild liver diseaseB18, K70.0-K70.3, K70.9, K71, K73, K74, K76.0Diabetes without end-organ damageICD-8: 249.00, 249.06, 249.07, 249.09, 250.00, 250.06, 250.07, 250.09; ICD-10: E10.0, E10.1, E10.9, E11.0, E11.1, E11.9Diabetes with end-organ damage2ICD-8: 249.01-249.05, 249.08, 250.01-250.05, 250.08; ICD-10: E10.2-E10.8, E11.2-E11.8HemiplegiaICD-8: 344; ICD-10: G81, G82Moderate to severe renal diseaseICD-8: 403, 404, 580-583, 584, 590.09, 593.19, 753.10-753.19, 792; ICD-10: I12, I13, N00-N05, N07, N11, N14, N17-N19, Q61Non-metastatic solid tumourICD-8: 140-194; ICD-10: C00-C75LeukaemiaICD-8: 204-207; ICD-10: C91-C95LymphomaICD-8: 200-203, 275.59; ICD-10: C81-C85, C88, C90, C96Moderate to severe liver disease3ICD-8: 070.00, 070.02, 070.04, 070.06, 070.08, 573.00, 456.00-456.09; ICD-10: B15.0, B16.0, B16.2, B19.0, K70.4, K72, K76.6, I85Metastatic cancer6ICD-8: 195-198, 199; ICD-10: C76-C80AIDSICD-8: 079.83; ICD-10: B21-B24Individual comorbiditiesMyocardial infarctionICD-8: 410; ICD-10: I21, I22, I23Congestive heart failureICD-8: 427.09, 427.10, 427.11, 427.19, 428.99, 782.49; ICD-10: I50, I11.0, I13.0, I13.2Angina pectorisICD-8: 413; ICD-10: I20.9, I25.1, I25.9Intermittent arterial claudicationICD-8: 443.89-443.99; ICD-10: I73.9COPDICD-8: 491-492; ICD-10: J41-44; ATC: R03Venous thromboembolismICD-8: 451.00; ICD-10: I80.1-3, I26Atrial fibrillation or flutterICD-8: 427.93, 427.94; ICD-10: I48Heart valve diseaseICD-8: 394-398; ICD-10: I05, I06, I07, I08.0, I09.8, I34-I37, I39.0, I39.3, I51.1A, Q22HypertensionICD-8: 400-404; ICD-10: I10-I15ObesityICD-8: 277; ICD-10: E65-E68Diabetes mellitusICD-8: 249-250; ICD-10: E10-E14, O24 (except O24.4), H36.0; ATC: A10B, A10AChronic kidney disease ICD-8: 249.02, 250.02, 753.10-753.19,?582, 583,?584, 590.09, 593.20, 792; ICD-10: E10.2, E11.2, E14.2, N03, N05, N11.0, N14, N16, N18-N19, N26.9, Q61.1-Q61.4Alcoholism-related diseases ICD-8: 291, 303, 456, 571.09, 571.10, 577.10; ICD-10: F10.1-9, G31.2, G62.1, G72.1, I 42.6, K29.2, K86.0, Z72.1; ATC: N07BBCancerICD-8: 140-207; ICD-10: C00-C96DementiaICD-8: 290.09-290.19, 293.09; ICD-10: F00-F03, F05.1, G30Osteoporosis ICD-8: 723.09; ICD-10: M80-M82Rheumatoid arthritis or connective tissue diseaseICD-8: 712, 716, 734, 446, 135.99; ICD-10: M05-M06, M30–M36, M45Rheumatoid arthritisICD-8: 712; ICD-10: M05-M06Systemic connective tissue diseaseICD-8: 716, 734, 446, 135.99; ICD-10: M30–M36, M45OsteoarthritisICD-8: 713; ICD-10: M015-19, M47Other pain-related conditionsMigraineICD-8: 346; ICD-10:?G43; ATC: N02CC; N02CARecent dental procedure Dental visit within 15 days before last NSAID prescription redemption identified from the Danish National Health Service RegistryTrauma or fractureICD-8: 800-929, 950-959; ICD-10: S00-T14 (within 60 days before last NSAID prescription redemption)Table e-2. Characteristics of stroke patients with current NSAID use, according to new and long-term use.NSAID useIschemic strokeIntracerebral hemorrhageSubarachnoid hemorrhageUnspecified strokeNew use(n=1,965)Long-term use(n=3,339)New use(n=476)Long-term use(n=737)New use(n=247)Long-term use(n=242)New use(n=1,324)Long-term use(n=2,505)Gender (female), %47.055.053.453.660.715351.657.8Age, %<60 years23.116.224.415.566.09419.313.760–69 years22.222.419.520.518.26020.818.870–79 years28.130.826.531.18.94027.430.3≥80 years26.730.629.633.06.94832.637.2Comorbidity level,* %Low49.242.446.242.171.712641.838.2Moderate37.341.839.542.221.98838.542.7High13.515.714.315.76.52819.719.1Individual comorbidities, %Myocardial infarction6.87.56.14.71.298.88.7Angina pectoris13.114.412.410.24.52815.717.1Atrial fibrillation or flutter10.211.112.210.73.61913.112.6Heart valve disease3.74.02.72.23.634.53.6Intermittent claudication3.32.92.92.20.443.33.6Venous thromboembolism3.43.73.84.21.684.24.7Obesity4.87.04.66.03.2134.86.3Diabetes mellitus11.514.97.811.04.92514.215.6Chronic kidney disease1.81.71.71.51.242.92.2Hypertension23.627.018.325.014.64527.528.5COPD21.225.920.423.214.65523.126.0Alcoholism-related disease7.27.19.56.06.5258.27.3Dementia1.62.73.64.3–63.22.8Cancer15.014.519.717.47.33118.216.5Rheumatoid arthritis1.24.02.34.33.6112.24.7Connective tissue disease2.53.72.53.72.4103.24.0Osteoarthritis20.132.116.629.39.37421.334.9Osteoporosis4.87.15.97.72.4235.76.3Comedications, %ACE or A2R inhibitors26.530.818.726.515.46127.029.8β-blockers19.121.914.515.17.32921.321.6Calcium channel blockers15.519.010.711.19.73116.817.2Diuretics25.734.424.626.312.66033.737.4Nitrates1.52.30.81.6–42.43.0Statins17.018.812.415.37.73715.517.5Acetylsalicylic acid23.228.118.121.26.14124.729.7Clopidogrel1.91.50.21.10.442.01.8Vitamin K antagonists3.03.39.08.83.255.24.2Systemic glucocorticoids6.47.74.84.74.097.38.4SSRIs7.911.411.611.76.12210.013.6Bisphosphonates3.15.35.05.42.8153.45.2CT or MRI scan during admission, %93.391.991.292.490.721681.080.2CT scan90.089.288.791.589.121579.278.9MRI scan17.212.99.76.88.5128.25.2Abbreviations: ACE, angiotensin-converting enzyme; A2R, angiotensin-2 receptor; NSAIDs, non-steroidal anti-inflammatory drugs, SSRIs, selective serotonin reuptake inhibitors*Three levels of comorbidity were defined based on Charlson Comorbidity Index scores of 0 (low), 1–2 (moderate), and ≥3 (high). Table e-3. Characteristics of stroke patients according to preadmission NSAID use in the propensity-score matched cohorts.Ischemic strokeIntracerebral hemorrhageSubarachnoid hemorrhageCurrent useNo useCurrent useNo useCurrent useNo usen%n%n%%nn%n%Total number (%)5304100530410012121001212100485100485100Gender (female)276152.1276852.264753.464953.531164.130262.3Age, years<6099318.797318.323619.523019.025151.825753.060–69118422.3115321.725020.624420.19820.210120.870–79158129.8157129.633227.435429.27715.96212.8≥80154629.1160730.339432.538431.75912.26513.4Comorbidity level*Low238444.9236344.656346.553043.730162.130362.5Moderate213040.2205638.845437.549941.214630.114229.3High79014.988516.719516.118315.1387.8408.2Individual comorbiditiesMyocardial infarction3867.33707.0594.9645.3173.5122.5Angina pectoris73913.971413.51189.713411.1357.2387.8Atrial fibrillation or flutter57110.855810.512710.513711.3244.9285.8Heart valve disease2063.91873.5393.2292.491.9122.5Intermittent claudication1603.01623.1312.6302.5102.151.0Venous thromboembolism1903.61813.4413.4494.071.4122.5Obesity3286.22965.6514.2665.4214.3183.7Diabetes mellitus72313.670813.313311.01189.7357.2347.0Chronic kidney disease931.8871.6262.1191.671.471.4Hypertension136525.7137125.828123.227122.48116.77916.3COPD128024.1132024.927022.326722.09519.68818.1Alcoholism-related disease3787.13787.1978.0897.3306.2418.5Dementia1232.31302.5443.6494.081.661.2Cancer77814.777514.621317.622118.2357.2459.3Rheumatoid arthritis1583.01633.1211.7423.5142.9193.9Connective tissue disease1753.31653.1363.0393.2102.1163.3Osteoarthritis146627.6147027.729324.229424.38818.19319.2Osteoporosis3306.23346.3776.4857.0224.5296.0ComedicationsACE or A2R inhibitors155029.2153929.027122.428423.49319.29720.0β-blockers110520.8110220.819315.918014.9459.3469.5Calcium channel blockers93717.792117.413611.213311.0489.95411.1Diuretics165231.1168431.733127.331125.79018.68818.1Nitrates1072.01072.0131.1161.361.240.8Statins96418.294317.816913.917214.25912.25511.3Acetylsalicylic acid139426.3138626.126621.924119.95110.55511.3Clopidogrel861.6841.6161.390.751.051.0Vitamin K antagonists1703.21693.2937.71088.9163.3132.7Systemic glucocorticoids3847.23697.0806.6574.7244.9173.5SSRIs53810.155210.416313.414111.6489.9367.4Bisphosphonates2374.52414.5584.8635.2204.1214.3CT or MRI scan during admission490492.5490592.5110190.8111491.944892.443790.1CT scan474789.5470688.7107989.0109590.344591.843289.1MRI scan76714.577714.6967.9967.9347.0336.8Abbreviations: ACE, angiotensin-converting enzyme; A2R, angiotensin-2 receptor; NSAIDs, non-steroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors*Three levels of comorbidity were defined based on Charlson Comorbidity Index scores of 0 (low), 1–2 (moderate), and ≥3 (high).Table e-4. Preadmission use of individual NSAIDs and 30-day mortality estimates following hemorrhagic stroke.Hazard ratio (95% CI)Intracerebral hemorrhageSubarachnoid hemorrhageUnadjustedMultivariable-adjusted*Propensity-scorematched*UnadjustedMultivariable-adjusted*Propensity-scorematched*No use (of any NSAIDs)1 (reference)1 (reference)1 (reference)1 (reference)1 (reference)1 (reference)Ibuprofen (current use)0.90 (0.77-1.04)0.92 (0.79-1.07)1.02 (0.83-1.26)0.83 (0.63-1.09)0.85 (0.64-1.12)0.86 (0.60-1.25)New use0.83 (0.67-1.02)0.85 (0.69-1.05)0.95 (0.73-1.22)0.64 (0.44-0.94)0.66 (0.45-0.97)0.67 (0.42-1.05)Long-term use0.98 (0.79-1.21)1.00 (0.81-1.24)1.12 (0.87-1.45)1.19 (0.80-1.75)1.19 (0.80-1.76)1.25 (0.79-1.97)Naproxen (current use)0.87 (0.50-1.49)0.92 (0.53-1.60)1.15 (0.53-2.50)0.49 (0.07-3.48)0.67 (0.09-4.77)0.50 (0.05-5.22)New use0.73 (0.33-1.62)0.91 (0.41-2.03)0.96 (0.36-2.58)---Long-term use1.04 (0.49-2.18)0.94 (0.45-1.98)1.40 (0.55-3.52)13.04 (1.83-92.82)18.54 (2.60-132.3)10.95 (1.57-76.29)Etodolac (current use)0.76 (0.52-1.12)0.72 (0.49-1.06)0.74 (0.45-1.22)1.12 (0.53-2.37)0.79 (0.37-1.67)0.99 (0.35-2.79)New use0.83 (0.43-1.59)0.81 (0.42-1.56)0.81 (0.38-1.69)0.82 (0.20-3.28)0.74 (0.18-3.00)0.73 (0.15-3.48)Long-term use0.74 (0.46-1.17)0.69 (0.43-1.09)0.71 (0.40-1.25)1.32 (0.55-3.19)0.81 (0.33-1.97)1.17 (0.38-3.57)Diclofenac (current use)0.98 (0.80-1.21)0.97 (0.79-1.20)0.92 (0.69-1.23)0.79 (0.53-1.18)0.84 (0.57-1.26)0.82 (0.48-1.40)New use0.79 (0.56-1.12)0.79 (0.56-1.12)0.74 (0.50-1.10)0.58 (0.32-1.05)0.66 (0.36-1.19)0.60 (0.30-1.19)Long-term use1.15 (0.88-1.49)1.12 (0.86-1.45)1.07 (0.78-1.49)1.12 (0.66-1.90)1.09 (0.64-1.86)1.16 (0.61-2.20)Celecoxib (current use)1.38 (0.62-3.08)1.26 (0.56-2.81)0.87 (0.29-2.60)1.26 (0.18-8.93)1.42 (0.20-10.16)0.82 (0.08-8.65)New use1.55 (0.58-4.12)1.52 (0.57-4.07)0.94 (0.29-3.04)---Long-term use1.15 (0.29-4.57)0.93 (0.23-3.73)0.76 (0.17-3.31)4.27 (0.60-30.37)3.45 (0.47-25.11)2.45 (0.38-15.82)Rofecoxib (current use)1.09 (0.41-2.90)1.13 (0.42-3.01)0.63 (0.18-2.22)1.85 (0.26-13.17)0.97 (0.13-7.27)0.71 (0.08-6.62)New use------Long-term use1.42 (0.53-3.79)1.51 (0.56-4.05)0.81 (0.23-2.83)3.86 (0.54-27.44)2.32 (0.26-20.56)1.41 (0.21-9.54)*See description of the multivariable-adjusted and propensity-score matched models in the text and in the footnote to Table 2. Table cells with only en-dash indicate subgroups with insufficient data for regression analyses.Table e-5. 30-day mortality estimates following stroke, comparing former and non-use of NSAIDs.Hazard ratio (95% confidence interval)Ischemic strokeIntracerebral hemorrhageSubarachnoid hemorrhageUnadjustedMultivariable-adjusted*Propensity-scorematched*UnadjustedMultivariable-adjusted*Propensity-scorematched*UnadjustedMultivariable-adjusted*Propensity-scorematched*No use of any NSAIDs1 (reference)1 (reference)1 (reference)1 (reference)1 (reference)1 (reference)1 (reference)1 (reference)1 (reference)Any NSAIDs (former use)0.78 (0.70-0.88)0.81 (0.72-0.91)0.84 (0.72-0.98)0.94 (0.84-1.06)0.93 (0.82-1.04)0.97 (0.83-1.14)0.69 (0.53-0.90)0.66 (0.51-0.85)0.63 (0.45-0.86)Nonselective NSAIDs (former use)0.78 (0.67-0.90)0.84 (0.73-0.98)0.81 (0.66-1.00)0.89 (0.76-1.04)0.91 (0.78-1.06)0.91 (0.75-1.10)0.67 (0.48-0.94)0.69 (0.49-0.97)0.59 (0.39-0.88)COX-2 inhibitors (former use)0.83 (0.68-1.01)0.84 (0.69-1.02)1.02 (0.76-1.38)1.16 (0.96-1.41)1.11 (0.91-1.34)1.21 (0.96-1.52)0.72 (0.47-1.11)0.68 (0.45-1.05)0.66 (0.41-1.08)Older types (former use)0.86 (0.70-1.04)0.88 (0.72-1.07)1.06 (0.78-1.45)1.15 (0.94-1.40)1.10 (0.90-1.35)1.18 (0.93-1.49)0.67 (0.43-1.05)0.66 (0.42-1.03)0.57 (0.34-0.96)Coxibs (former use)0.54 (0.23-1.31)0.40 (0.17-0.97)0.50 (0.13-2.00)1.31 (0.70-2.44)1.21 (0.65-2.25)1.75 (0.89-3.44)2.33 (0.75-7.23)1.22 (0.38-3.89)6.23 (3.11-12.48)*See description of the multivariable-adjusted and propensity-score matched models in the text and in the footnote to Table 2.e-Table 6. Preadmission NSAID use and 30-day mortality estimates following stroke.Ischemic stroke (ICD-10 codes: I63-I64)Ischemic stroke (ICD-10 code: I63)Unspecified stroke (ICD-10 code: I64)30-day mortality riskHazard ratio (95% CI)30-day mortality riskHazard ratio (95% CI)30-day mortalityriskHazard ratio (95% CI)UnadjustedMultivariable-adjusted*Propensity-score- matched?UnadjustedMultivariable-adjusted*Propensity-score- matched?UnadjustedMultivariable-adjusted*Propensity-score- matched?No use of any NSAIDs10.9 (10.6-11.1)1 (reference)1 (reference)1 (reference)8.7 (8.4-9.0)1 (reference)1 (reference)1 (reference)14.3 (13.9-14.8)1 (reference)1 (reference)1 (reference)Any NSAIDs?11.1 (10.5-11.8)1.03 (0.96-1.10)1.02 (0.96-1.09)1.03 (0.94-1.12)8.8 (8.1-9.6)1.01 (0.92-1.11)1.02 (0.93-1.13)0.99 (0.87-1.12)14.4 (13.3-15.5)1.00 (0.92-1.10)1.00 (0.91-1.09)0.99 (0.88-1.12)New use11.4 (10.3-12.5)1.05 (0.95-1.16)1.11 (1.00-1.23)1.15 (0.99-1.34)9.3 (8.1-10.6)1.07 (0.92-1.24)1.17 (1.00-1.35)1.18 (0.95-1.47)14.5 (12.7-16.6)1.01 (0.88-1.17)1.04 (0.90-1.20)1.25 (1.01-1.54)Long-term use11.0 (10.2-11.8)1.01 (0.93-1.10)0.97 (0.90-1.06)1.00 (0.89-1.11)8.5 (7.6-9.5)0.98 (0.87-1.11)0.94 (0.83-1.07)0.93 (0.79-1.09)14.3 (13.0-15.7)1.00 (0.89-1.11)0.98 (0.87-1.09)0.96 (0.83-1.12)Nonselective NSAIDs?10.8 (9.9-11.7)0.99 (0.90-1.09)1.06 (0.97-1.17)1.11 (0.97-1.26)8.1 (7.1-9.2)0.93 (0.81-1.06)1.00 (0.87-1.15)1.02 (0.85-1.24)14.7 (13.2-16.4)1.03 (0.91-1.16)1.11 (0.98-1.25)1.27 (1.06-1.52)New use10.4 (9.1-11.7)0.95 (0.83-1.09)1.06 (0.93-1.21)1.06 (0.90-1.25)8.0 (6.6-9.6)0.91 (0.75-1.11)1.04 (0.85-1.26)1.01 (0.80-1.28)14.1 (11.8-16.6)0.98 (0.82-1.18)1.07 (0.89-1.29)1.21 (0.96-1.52)Long-term use11.1 (9.9-12.5)1.02 (0.91-1.16)1.07 (0.94-1.21)1.15 (0.98-1.33)8.2 (6.8-9.7)0.94 (0.78-1.13)0.97 (0.80-1.17)1.04 (0.83-1.30)15.3 (13.2-17.7)1.07 (0.91-1.26)1.13 (0.96-1.33)1.32 (1.07-1.62)COX-2 inhibitors?12.7 (11.5-13.9)1.18 (1.06-1.30)1.14 (1.03-1.27)1.16 (1.01-1.34)10.4 (9.1-11.9)1.20 (1.04-1.40)1.19 (1.02-1.38)1.10 (0.89-1.36)15.4 (13.7-17.4)1.09 (0.95-1.25)1.07 (0.93-1.22)1.10 (0.91-1.34)New use14.0 (12.2-16.0)1.30 (1.12-1.51)1.31 (1.13-1.52)1.28 (1.07-1.54)11.4 (9.3-14.0)1.33 (1.06-1.65)1.42 (1.14-1.77)1.21 (0.93-1.58)17.3 (14.4-20.7)1.22 (1.00-1.50)1.18 (0.96-1.45)1.24 (0.97-1.59)Long-term use11.8 (10.4-13.3)1.09 (0.96-1.25)1.04 (0.91-1.19)1.08 (0.91-1.28)9.7 (8.1-11.7)1.12 (0.92-1.37)1.05 (0.86-1.28)1.02 (0.80-1.31)14.3 (12.1-16.8)1.00 (0.84-1.20)0.99 (0.83-1.19)1.02 (0.82-1.28)Older types12.6 (11.5-13.8)1.17 (1.06-1.30)1.16 (1.04-1.28)1.18 (1.02-1.37)10.4 (9.0-11.9)1.20 (1.03-1.40)1.20 (1.03-1.40)1.31 (1.04-1.64)15.4 (13.6-17.4)1.08 (0.94-1.24)1.08 (0.94-1.24)1.01 (0.83-1.22)New use13.8 (12.0-15.9)1.29 (1.11-1.50)1.30 (1.12-1.52)1.30 (1.08-1.56)11.4 (9.2-14.0)1.32 (1.06-1.65)1.42 (1.14-1.78)1.44 (1.09-1.89)17.1 (14.2-20.5)1.20 (0.98-1.48)1.16 (0.95-1.43)1.12 (0.88-1.43)Long-term use11.8 (10.4-13.3)1.09 (0.95-1.25)1.06 (0.93-1.22)1.10 (0.93-1.31)9.7 (8.0-11.7)1.12 (0.91-1.37)1.06 (0.86-1.30)1.22 (0.94-1.58)14.2 (12.0-16.8)1.00 (0.83-1.20)1.02 (0.85-1.23)0.94 (0.75-1.17)Coxibs13.5 (8.5-21.0)1.25 (0.76-2.04)0.87 (0.53-1.42)1.06 (0.53-2.15)10.8 (5.3-21.3)1.23 (0.59-2.58)0.87 (0.41-1.82)0.97 (0.34-2.75)16.7 (9.0-29.6)1.19 (0.62-2.29)0.82 (0.42-1.57)1.00 (0.40-2.49)New use22.9 (12.2-40.5)2.27 (1.14-4.54)1.48 (0.74-2.96)1.93 (0.82-4.53)15.0 (5.1-39.6)1.75 (0.56-5.43)1.14 (0.37-3.53)1.41 (0.37-5.31)33.3 (15.4-62.5)2.71 (1.13-6.52)1.70 (0.71-4.10)2.22 (0.75-6.53)Long-term use9.5 (4.9-18.1)0.86 (0.43-1.72)0.61 (0.31-1.23)0.73 (0.31-1.72)8.9 (3.4-22.0)1.00 (0.37-2.67)0.74 (0.28-1.97)0.79 (0.24-2.65)10.3 (4.0-25.1)0.70 (0.26-1.87)0.49 (0.18-1.32)0.59 (0.18-1.88) Table e-7. Preadmission NSAID use and 30-day mortality following strokes listed as primary diagnoses in the Danish National Registry of PatientsAdjusted hazard ratio (95% confidence interval)Ischemic strokeIntracerebral hemorrhageSubarachnoid hemorrhageIncluding unspecified diagnosesNot including unspecified diagnosesNo use of any NSAIDs1 (reference)1 (reference)1 (reference)1 (reference)Any NSAIDs1.01 (0.93-1.10)0.99 (0.88-1.12)1.03 (0.92-1.15)0.80 (0.64-1.00)New use1.12 (0.99-1.28)1.16 (0.97-1.38)0.89 (0.74-1.08)0.65 (0.46-0.94)Long-term use0.96 (0.86-1.06)0.91 (0.79-1.05)1.11 (0.97-1.27)0.92 (0.70-1.21)Nonselective NSAIDs?1.09 (0.97-1.22)1.07 (0.91-1.26)0.97 (0.83-1.13)0.83 (0.63-1.11)New use1.07 (0.91-1.27)1.08 (0.86-1.36)0.85 (0.68-1.06)0.66 (0.44-1.00)Long-term use1.11 (0.95-1.29)1.06 (0.85-1.32)1.11 (0.91-1.36)1.08 (0.73-1.60)COX-2 inhibitors1.09 (0.96-1.24)1.01 (0.83-1.22)1.02 (0.85-1.23)0.82 (0.56-1.19)New use1.25 (1.03-1.52)1.17 (0.88-1.57)0.92 (0.67-1.26)0.58 (0.31-1.09)Long-term use1.00 (0.85-1.18)0.92 (0.71-1.18)1.09 (0.87-1.36)1.07 (0.67-1.71)Older types1.11 (0.97-1.27)1.03 (0.85-1.25)1.00 (0.83-1.22)0.81 (0.55-1.20)New use1.22 (1.00-1.49)1.19 (0.89-1.59)0.89 (0.64-1.24)0.61 (0.33-1.14)Long-term use1.04 (0.88-1.24)0.94 (0.73-1.21)1.07 (0.85-1.35)1.04 (0.64-1.70)Coxibs0.73 (0.38-1.41)0.55 (0.18-1.70)1.24 (0.66-2.31)0.96 (0.22-4.25)New use1.90 (0.90-3.99)1.17 (0.29-4.70)1.10 (0.41-2.94)–Long-term use0.23 (0.06-0.93)0.26 (0.04-1.88)1.35 (0.60-3.04)–See description of the multivariable-adjusted model and NSAID categories in the text and in the footnote to Table 2. Table cells with only en-dash indicate subgroups with insufficient data for regression analyses.Table e-8. Preadmission NSAID use and 30-day mortality estimates following stroke confirmed by CT or MRI.Ischemic strokeIntracerebral hemorrhageSubarachnoid hemorrhage30-daymortality riskHazard ratio (95% CI)30-daymortality riskHazard ratio (95% CI)30-daymortality riskHazard ratio (95% CI)UnadjustedMultivariable-adjusted*UnadjustedMultivariable-adjusted*UnadjustedMultivariable-adjusted*No use of any NSAIDs8.4 (8.1-8.7)1 (reference)1 (reference)35.2 (34.2-36.2)1 (reference)1 (reference)25.0 (23.6-26.5)1 (reference)1 (reference)Any NSAIDs8.5 (7.8-9.3)1.01 (0.91-1.12)1.02 (0.92-1.13)34.2 (31.5-37.1)0.96 (0.86-1.07)0.95 (0.85-1.06)22.5 (18.9-26.7)0.88 (0.72-1.09)0.85 (0.69-1.06)New use9.2 (8.0-10.6)1.10 (0.94-1.28)1.20 (1.02-1.40)30.9 (26.8-35.5)0.85 (0.72-1.02)0.86 (0.72-1.03)16.6 (12.3-22.1)0.62 (0.45-0.86)0.67 (0.48-0.94)Long-term use8.1 (7.2-9.1)0.96 (0.84-1.09)0.92 (0.81-1.05)36.3 (32.8-40.0)1.03 (0.91-1.17)1.01 (0.88-1.15)28.7 (23.2-35.3)1.18 (0.91-1.53)1.03 (0.79-1.34)Nonselective NSAIDs?7.9 (6.9-9.0)0.93 (0.81-1.08)1.01 (0.87-1.16)32.5 (28.9-36.4)0.91 (0.79-1.05)0.93 (0.80-1.07)21.7 (17.1-27.2)0.84 (0.64-1.11)0.90 (0.68-1.18)New use7.9 (6.5-9.6)0.94 (0.76-1.15)1.06 (0.87-1.31)30.1 (25.3-35.5)0.83 (0.67-1.02)0.85 (0.69-1.04)16.2 (11.3-22.9)0.61 (0.41-0.90)0.64 (0.43-0.94)Long-term use7.8 (6.5-9.4)0.93 (0.76-1.13)0.96 (0.78-1.17)35.0 (29.9-40.7)0.99 (0.82-1.21)1.02 (0.84-1.24)30.7 (22.5-40.8)1.28 (0.89-1.84)1.38 (0.95-1.99)COX-2 inhibitors10.0 (8.6-11.6)1.19 (1.02-1.40)1.17 (1.00-1.37)33.4 (28.7-38.7)0.92 (0.76-1.10)0.91 (0.75-1.09)22.2 (16.3-29.9)0.87 (0.61-1.24)0.84 (0.59-1.20)New use11.2 (9.0-13.8)1.34 (1.07-1.69)1.41 (1.12-1.77)29.0 (22.0-37.6)0.78 (0.57-1.07)0.79 (0.57-1.09)16.7 (10.0-27.0)0.63 (0.36-1.09)0.69 (0.40-1.20)Long-term use9.2 (7.5-11.2)1.09 (0.88-1.35)1.02 (0.82-1.26)36.1 (30.1-42.9)1.01 (0.80-1.26)0.98 (0.78-1.22)28.8 (19.4-41.3)1.18 (0.75-1.86)1.00 (0.63-1.59)Older types10.1 (8.7-11.7)1.20 (1.02-1.41)1.20 (1.02-1.41)32.5 (27.7-37.9)0.89 (0.73-1.08)0.89 (0.73-1.08)21.6 (15.6-29.4)0.85 (0.59-1.22)0.83 (0.57-1.19)New use11.1 (9.0-13.8)1.33 (1.06-1.68)1.41 (1.12-1.78)28.5 (21.3-37.3)0.76 (0.55-1.06)0.78 (0.56-1.10)17.3 (10.5-28.0)0.66 (0.38-1.14)0.73 (0.42-1.27)Long-term use9.3 (7.6-11.4)1.11 (0.89-1.38)1.05 (0.85-1.31)35.0 (28.9-42.0)0.97 (0.77-1.23)0.94 (0.75-1.20)26.6 (17.4-39.2)1.09 (0.68-1.77)0.93 (0.57-1.52)Coxibs8.2 (3.5-18.6)0.96 (0.40-2.30)0.66 (0.27-1.59)45.8 (28.6-67.3)1.31 (0.72-2.37)1.19 (0.65-2.15)40.0 (11.8-87.4)1.46 (0.37-5.84)1.11 (0.27-4.61)New use15.8 (5.4-41.3)1.92 (0.62-5.94)1.19 (0.38-3.70)36.4 (15.5-70.3)0.98 (0.37-2.61)0.87 (0.32-2.32)---Long-term use4.8 (1.2-17.7)0.55 (0.14-2.19)0.40 (0.10-1.59)53.9 (30.4-80.8)1.62 (0.77-3.40)1.50 (0.71-3.17)---See description of the multivariable-adjusted model and NSAID categories in the text and in the footnote to Table 2. Table cells with only en-dash indicate subgroups with insufficient data for regression analyses.Table e-9. Sensitivity analysis of the association between preadmission NSAID use and 30-day stroke mortality using a 30-day instead of a 60-day exposure window of NSAID use.Ischemic strokeIntracerebral hemorrhageSubarachnoid hemorrhage30-daymortality riskHazard ratio (95% CI)30-daymortality riskHazard ratio (95% CI)30-daymortality riskHazard ratio (95% CI)UnadjustedMultivariable-adjusted*UnadjustedMultivariable-adjusted*UnadjustedMultivariable-adjusted*No use of any NSAIDs8.7 (8.4-9.0)1 (reference)1 (reference)35.1 (34.1-36.0)1 (reference)1 (reference)24.5 (23.1-25.9)1 (reference)1 (reference)Any NSAIDs8.7 (7.8-9.7)1.00 (0.88-1.13)1.00 (0.88-1.12)35.5 (32.3-38.9)1.01 (0.89-1.14)0.98 (0.87-1.11)20.6 (16.7-25.4)0.82 (0.64-1.05)0.81 (0.63-1.04)New use8.9 (7.3-10.8)1.03 (0.83-1.26)1.14 (0.93-1.40)30.3 (25.1-36.3)0.83 (0.66-1.03)0.85 (0.68-1.06)11.9 (7.7-18.2)0.45 (0.28-0.71)0.50 (0.31-0.80)Long-term use8.6 (7.5-9.8)0.98 (0.85-1.14)0.94 (0.81-1.08)38.1 (34.1-42.4)1.10 (0.96-1.27)1.06 (0.91-1.22)28.1 (22.1-35.4)1.18 (0.89-1.58)1.04 (0.78-1.39)Nonselective NSAIDs8.1 (7.1-9.2)0.93 (0.81-1.06)1.00 (0.87-1.15)32.4 (28.2-37.1)0.91 (0.76-1.08)0.93 (0.78-1.10)20.1 (15.1-26.4)0.80 (0.58-1.10)0.86 (0.63-1.19)New use8.0 (6.6-9.6)0.91 (0.75-1.11)1.04 (0.85-1.26)28.7 (22.8-35.9)0.77 (0.59-1.02)0.83 (0.63-1.09)11.7 (6.9-19.2)0.44 (0.26-0.76)0.49 (0.28-0.85)Long-term use8.2 (6.8-9.7)0.94 (0.78-1.13)0.97 (0.80-1.17)35.3 (29.6-41.7)1.02 (0.82-1.26)1.01 (0.81-1.25)31.5 (22.6-42.7)1.35 (0.92-2.00)1.37 (0.93-2.03)COX-2 inhibitors10.4 (9.1-11.9)1.20 (1.04-1.40)1.19 (1.02-1.38)38.1 (32.4-44.5)1.09 (0.89-1.34)1.08 (0.88-1.32)20.8 (14.2-29.8)0.85 (0.56-1.30)0.81 (0.53-1.24)New use11.4 (9.3-14.0)1.33 (1.06-1.65)1.42 (1.14-1.77)32.6 (23.9-43.4)0.91 (0.63-1.30)0.90 (0.63-1.31)13.0 (6.4-25.3)0.51 (0.24-1.07)0.58 (0.28-1.22)Long-term use9.7 (8.1-11.7)1.12 (0.92-1.37)1.05 (0.86-1.28)41.3 (34.0-49.5)1.20 (0.94-1.54)1.18 (0.92-1.51)28.9 (18.5-43.2)1.25 (0.75-2.08)1.00 (0.60-1.68)Older types10.4 (9.0-11.9)1.20 (1.03-1.40)1.20 (1.03-1.40)37.2 (31.2-43.8)1.06 (0.85-1.32)1.06 (0.85-1.32)20.2 (13.7-29.3)0.83 (0.54-1.28)0.80 (0.52-1.24)New use11.4 (9.2-13.9)1.32 (1.06-1.65)1.42 (1.14-1.78)31.3 (22.5-42.5)0.86 (0.58-1.26)0.88 (0.60-1.29)13.0 (6.4-25.3)0.51 (0.24-1.07)0.58 (0.27-1.22)Long-term use9.7 (8.0-11.7)1.12 (0.91-1.37)1.06 (0.86-1.30)40.6 (33.1-49.1)1.18 (0.91-1.53)1.17 (0.90-1.51)28.0 (17.6-42.7)1.22 (0.72-2.07)1.00 (0.58-1.70)Coxibs10.8 (5.3-21.3)1.23 (0.59-2.58)0.87 (0.41-1.82)50.0 (30.0-74.1)1.48 (0.77-2.84)1.23 (0.64-2.37)---New use15.0 (5.1-39.6)1.75 (0.56-5.43)1.14 (0.37-3.53)44.4 (20.0-80.0)1.33 (0.50-3.55)1.11 (0.42-2.97)---Long-term use8.9 (3.4-22.0)1.00 (0.37-2.67)0.74 (0.28-1.97)55.6 (28.1-86.4)1.63 (0.68-3.90)1.35 (0.56-3.25)---*See description of the multivariable-adjusted model and NSAID categories in the text and in the footnote to Table 2. Table cells with only en-dash indicate subgroups with insufficient data for regression analyses.Table e-10. Preadmission NSAID use and 30-day mortality after stroke, stratified analyses.Multivariable-adjusted hazard ratio (95% CI)(95% CI)*Ischemic strokeIntracerebral hemorrhageSubarachnoid hemorrhageMenNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs0.95 (0.77-1.18)0.90 (0.73-1.10)0.98 (0.65-1.48)New use1.06 (0.80-1.42)0.86 (0.64-1.15)0.61 (0.31-1.19)Long-term use0.85 (0.62-1.15)0.94 (0.72-1.24)1.48 (0.88-2.49)COX-2 inhibitors1.24 (0.98-1.57)1.00 (0.77-1.30)0.96 (0.52-1.78)New use1.43 (1.01-2.00)0.89 (0.59-1.35)0.84 (0.34-2.04)Long-term use1.10 (0.80-1.52)1.09 (0.79-1.51)1.13 (0.49-2.65)WomenNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs1.03 (0.86-1.24)0.96 (0.79-1.17)0.78 (0.55-1.11)New use1.00 (0.76-1.30)0.88 (0.68-1.15)0.63 (0.38-1.02)Long-term use1.06 (0.84-1.35)1.06 (0.81-1.39)1.03 (0.63-1.68)COX-2 inhibitors1.16 (0.95-1.41)0.88 (0.70-1.12)0.81 (0.53-1.21)New use1.41 (1.05-1.88)0.86 (0.58-1.27)0.62 (0.32-1.20)Long-term use1.02 (0.79-1.32)0.89 (0.67-1.19)1.00 (0.60-1.69)Age < 60 yearsNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs1.09 (0.70-1.69)0.64 (0.43-0.94)0.85 (0.57-1.27)New use1.24 (0.71-2.17)0.59 (0.35-1.00)0.74 (0.45-1.23)Long-term use0.89 (0.46-1.75)0.69 (0.39-1.21)1.11 (0.60-2.05)COX-2 inhibitors1.36 (0.83-2.22)0.61 (0.34-1.09)0.97 (0.58-1.63)New use2.13 (1.16-3.93)0.36 (0.12-1.13)0.82 (0.42-1.60)Long-term use0.84 (0.39-1.80)0.81 (0.41-1.59)1.36 (0.60-3.09)Age 60-69 yearsNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs0.75 (0.49-1.15)0.97 (0.70-1.34)0.84 (0.45-1.56)New use0.88 (0.49-1.56)0.92 (0.57-1.47)0.72 (0.29-1.79)Long-term use0.65 (0.36-1.20)1.03 (0.67-1.57)1.03 (0.44-2.41)COX-2 inhibitors1.41 (0.95-2.09)0.75 (0.46-1.23)1.01 (0.48-2.13)New use1.60 (0.92-2.78)0.95 (0.49-1.85)0.33 (0.05-2.39)Long-term use1.26 (0.74-2.17)0.61 (0.30-1.24)1.54 (0.66-3.58)Age 70-79 yearsNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs1.07 (0.82-1.41)1.02 (0.80-1.32)0.68 (0.30-1.55)New use1.09 (0.73-1.63)0.96 (0.67-1.37)–Long-term use1.05 (0.73-1.51)1.10 (0.78-1.56)1.62 (0.69-3.81)COX-2 inhibitors1.18 (0.87-1.61)1.01 (0.75-1.36)0.84 (0.39-1.81)New use0.92 (0.54-1.56)0.84 (0.50-1.41)0.86 (0.27-2.74)Long-term use1.37 (0.95-1.98)1.12 (0.79-1.61)0.84 (0.30-2.32)Age ≥ 80 yearsNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs1.03 (0.85-1.24)0.93 (0.73-1.17)1.04 (0.60-1.80)New use1.04 (0.79-1.36)0.91 (0.66-1.26)0.69 (0.27-1.80)Long-term use1.03 (0.80-1.32)0.94 (0.68-1.30)1.29 (0.66-2.52)COX-2 inhibitors1.08 (0.88-1.33)1.01 (0.78-1.32)0.53 (0.21-1.35)New use1.43 (1.06-1.94)1.02 (0.67-1.56)0.55 (0.07-4.09)Long-term use0.89 (0.67-1.18)1.00 (0.72-1.40)0.52 (0.18-1.49)Rheumatoid arthritis No use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs0.84 (0.36-1.99)0.92 (0.34-2.49)–New use1.68 (0.50-5.66)––Long-term use0.55 (0.17-1.81)1.80 (0.64-5.08)–COX-2 inhibitors1.13 (0.50-2.55)1.61 (0.66-3.93)–New use–0.77 (0.15-4.11)–Long-term use1.32 (0.59-2.99)2.35 (0.82-6.71)–No rheumatoid arthritisNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs1.00 (0.87-1.15)0.94 (0.81-1.08)0.87 (0.66-1.13)New use1.02 (0.84-1.25)0.90 (0.74-1.09)0.62 (0.42-0.93)Long-term use0.98 (0.81-1.19)0.98 (0.80-1.19)1.24 (0.87-1.76)COX-2 inhibitors1.19 (1.02-1.39)0.91 (0.76-1.09)0.90 (0.64-1.27)New use1.45 (1.16-1.80)0.86 (0.64-1.15)0.75 (0.44-1.28)Long-term use1.03 (0.84-1.27)0.94 (0.75-1.18)1.06 (0.67-1.66)OsteoarthritisNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs1.06 (0.82-1.39)0.99 (0.74-1.33)0.89 (0.45-1.79)New use1.35 (0.92-1.99)1.04 (0.66-1.64)0.46 (0.11-2.03)Long-term use0.91 (0.64-1.29)0.96 (0.67-1.38)1.16 (0.53-2.54)COX-2 inhibitors1.14 (0.85-1.53)0.78 (0.55-1.13)2.53 (1.35-4.75)New use1.38 (0.84-2.27)0.40 (0.18-0.90)3.83 (1.24-11.79)Long-term use1.06 (0.74-1.50)1.02 (0.68-1.52)2.24 (1.08-4.65)No osteoarthritisNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs0.99 (0.84-1.16)0.92 (0.78-1.07)0.84 (0.63-1.13)New use0.96 (0.77-1.21)0.85 (0.68-1.05)0.63 (0.42-0.96)Long-term use1.01 (0.81-1.27)1.01 (0.80-1.26)1.23 (0.82-1.84)COX-2 inhibitors1.21 (1.02-1.45)0.99 (0.81-1.21)0.68 (0.44-1.04)New use1.43 (1.12-1.83)1.04 (0.77-1.41)0.55 (0.29-1.02)Long-term use1.06 (0.83-1.35)0.95 (0.74-1.24)0.86 (0.48-1.54)Myocardial infarctionNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs1.40 (0.97-2.02)1.13 (0.69-1.87)0.38 (0.04-3.45)New use1.24 (0.71-2.16)1.54 (0.81-2.92)0.47 (0.05-4.52)Long-term use1.55 (0.96-2.49)0.81 (0.37-1.76)–COX-2 inhibitors1.06 (0.66-1.71)1.48 (0.75-2.92)1.34 (0.18-9.92)New use1.93 (1.10-3.37)2.19 (0.73-6.60)–Long-term use0.49 (0.20-1.18)1.21 (0.52-2.82)1.34 (0.18-9.92)No myocardial infarctionNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs0.95 (0.82-1.11)0.92 (0.79-1.06)0.86 (0.66-1.12)New use1.01 (0.82-1.24)0.83 (0.68-1.02)0.61 (0.41-0.91)Long-term use0.91 (0.74-1.11)1.02 (0.83-1.24)1.23 (0.86-1.75)COX-2 inhibitors1.20 (1.03-1.41)0.90 (0.75-1.08)0.87 (0.62-1.23)New use1.34 (1.06-1.71)0.83 (0.62-1.12)0.71 (0.42-1.20)Long-term use1.12 (0.91-1.37)0.94 (0.75-1.18)1.06 (0.67-1.67)Atrial fibrillationNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs1.01 (0.76-1.34)1.14 (0.79-1.64)0.65 (0.22-1.90)New use1.12 (0.76-1.66)1.05 (0.65-1.68)0.32 (0.06-1.76)Long-term use0.91 (0.60-1.38)1.27 (0.74-2.19)1.20 (0.33-4.36)COX-2 inhibitors1.08 (0.78-1.50)1.24 (0.84-1.85)1.12 (0.33-3.79)New use1.17 (0.69-1.99)0.78 (0.41-1.48)21.44 (1.17-394.2)Long-term use1.04 (0.69-1.56)1.89 (1.15-3.12)0.85 (0.22-3.33)No atrial fibrillationNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs0.99 (0.85-1.16)0.90 (0.78-1.05)0.88 (0.67-1.17)New use1.00 (0.80-1.26)0.84 (0.68-1.04)0.64 (0.43-0.96)Long-term use0.98 (0.80-1.21)0.97 (0.79-1.20)1.25 (0.87-1.82)COX-2 inhibitors1.22 (1.03-1.44)0.88 (0.72-1.06)0.87 (0.61-1.24)New use1.49 (1.17-1.90)0.87 (0.64-1.20)0.67 (0.39-1.16)Long-term use1.05 (0.84-1.32)0.88 (0.69-1.12)1.11 (0.70-1.77)HypertensionNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs1.12 (0.89-1.41)0.92 (0.67-1.25)0.88 (0.50-1.52)New use1.17 (0.84-1.63)1.02 (0.65-1.59)0.73 (0.36-1.48)Long-term use1.08 (0.79-1.47)0.84 (0.55-1.28)1.19 (0.51-2.77)COX-2 inhibitors1.03 (0.76-1.38)0.97 (0.69-1.35)0.76 (0.28-2.10)New use1.16 (0.73-1.82)1.17 (0.70-1.97)0.67 (0.09-4.91)Long-term use0.95 (0.65-1.40)0.86 (0.56-1.33)0.80 (0.25-2.60)No hypertensionNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs0.94 (0.79-1.12)0.93 (0.79-1.08)0.84 (0.61-1.14)New use0.98 (0.77-1.25)0.84 (0.68-1.05)0.55 (0.34-0.90)Long-term use0.91 (0.72-1.16)1.03 (0.83-1.28)1.22 (0.82-1.80)COX-2 inhibitors1.26 (1.06-1.50)0.91 (0.74-1.11)0.96 (0.67-1.37)New use1.54 (1.20-1.98)0.77 (0.55-1.08)0.74 (0.43-1.29)Long-term use1.09 (0.86-1.37)1.00 (0.78-1.28)1.22 (0.76-1.96)DiabetesNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs0.99 (0.71-1.38)0.89 (0.59-1.34)0.84 (0.29-2.45)New use1.17 (0.72-1.90)1.08 (0.63-1.87)0.48 (0.09-2.45)Long-term use0.87 (0.55-1.36)0.72 (0.40-1.30)0.94 (0.25-3.48)COX-2 inhibitors0.95 (0.64-1.41)0.71 (0.40-1.25)3.61 (1.18-10.98)New use1.03 (0.55-1.94)0.64 (0.23-1.75)2.32 (0.50-10.79)Long-term use0.91 (0.55-1.50)0.74 (0.38-1.44)6.15 (1.40-27.09)No diabetesNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs1.00 (0.86-1.16)0.93 (0.80-1.08)0.84 (0.63-1.11)New use1.01 (0.82-1.26)0.85 (0.69-1.05)0.59 (0.39-0.89)Long-term use0.99 (0.80-1.21)1.02 (0.83-1.25)1.25 (0.87-1.81)COX-2 inhibitors1.23 (1.05-1.45)0.95 (0.79-1.14)0.81 (0.57-1.17)New use1.50 (1.18-1.89)0.88 (0.65-1.18)0.64 (0.36-1.13)Long-term use1.07 (0.86-1.33)0.99 (0.79-1.25)1.01 (0.63-1.60)COPDNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs0.87 (0.66-1.16)1.14 (0.88-1.48)0.65 (0.34-1.24)New use0.83 (0.54-1.27)1.14 (0.79-1.65)0.33 (0.10-1.06)Long-term use0.90 (0.63-1.30)1.15 (0.81-1.63)1.02 (0.48-2.16)COX-2 inhibitors0.93 (0.68-1.27)0.73 (0.49-1.09)0.93 (0.42-2.03)New use1.40 (0.89-2.18)0.67 (0.34-1.30)0.64 (0.15-2.67)Long-term use0.70 (0.45-1.08)0.76 (0.46-1.26)1.13 (0.44-2.87)No COPDNo use of any NSAIDs1 (reference)1 (reference)1 (reference)Nonselective NSAIDs1.05 (0.90-1.23)0.87 (0.73-1.02)0.91 (0.68-1.22)New use1.11 (0.89-1.39)0.80 (0.63-1.01)0.67 (0.44-1.02)Long-term use0.99 (0.80-1.24)0.94 (0.75-1.19)1.33 (0.89-1.99)COX-2 inhibitors1.28 (1.08-1.52)1.00 (0.83-1.22)0.92 (0.63-1.35)New use1.43 (1.11-1.84)0.95 (0.69-1.30)0.76 (0.43-1.34)Long-term use1.18 (0.94-1.47)1.04 (0.82-1.32)1.13 (0.69-1.85)*See description of the multivariable-adjusted model and NSAID categories in the text and in the footnote to Table 2. Table cells with only en-dash indicate subgroups with insufficient data for regression analyses.Figure e1. Propensity score distributions among NSAID users and non-users.A. Ischemic stroke B. Intracerebral hemorrhage C. Subarachnoid hemorrhageThe propensity score for NSAID use is the probability given baseline variables that any patient in either exposure group would be using NSAIDs. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download